Our Proprietary Platform Targets all Major diseases associated with
Advancing the Potential of a Novel Activation of the Pancreas
The company has focused on, and successfully achieved, the creation of a new chemical class based on its novel design strategy.
GPR119 is a g protein-coupled receptor expressed predominantly in the pancreas (β-cells) and gastrointestinal tract (enteroendocrine cells) in humans. in vitro studies have indicated a role for gpr119 in the modulation of insulin release by pancreatic β-cells and of glp-1, gip and pyy secretion by gut enteroendocrine cells.
The company has utilized smart drug discovery techniques, contracting teams of chemists and biologists who have leveraged new information and tools to more rationally develop interventions for targeting the complex pathology of Diabetes.
Overseen by a world class scientific team, Pramana has utilized their expertise in the development of its potent, selective and proprietary wholly owned GPR119 portfolio.
Pramana has focused its design strategy on novel and proprietary structures to differentiate its agonists. This strategy has led to the discovery of potent and selective agonists of GPR119 forT2DM treatment. three chemical series have been validated and optimized.
In early 2018, the company received the results of a PK study conducted on six potential lead compounds. The study was benchmarked against a literature-standard GPR119 agonist which advanced to Phase 2 clinical trials.
In early 2019 the company reached an important milestone with a successful in vivo study for a lead candidate. Further differentiating efficacy profiling is ongoing and advancing.